Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.
Read Full NewsImmune checkpoint inhibitors have been FDA-approved for head and neck cancer for a decade, but their use has only marginally increased among patients younger than 65.
As the first chemotherapy-free regimen to beat gemcitabine/cisplatin, perioperative enfortumab vedotin plus pembrolizumab could shift muscle-invasive bladder cancer care — but questions remain.
Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
1.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
2.
A new theranostic drug targets different cancer types.
3.
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
4.
Investigations may result in novel combination therapies for early-stage lung cancers.
5.
A better option for mild to moderate depression?
1.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
2.
Claudin-18.2 in Gastric Cancer: Tumor-Stroma Crosstalk and Disease Progression
3.
Advancements in Cancer Treatment Strategies for Non-Hodgkin Lymphoma
4.
Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma
5.
Mastering Breast Cancer Care in 2025: Diagnosis, Treatment, Education, and Innovation
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part XVI
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge